Global Microbiomes Market: Insights & Forecast with Potential Impact of COVID-19 (2020-2024)

Global Microbiomes Market: Insights & Forecast with Potential Impact of COVID-19 (2020-2024)

The global microbiomes market is forecasted to reach US$9,376 million in 2024, growing at a CAGR of 135.47% for the period spanning 2018-2024. The factors such as growing geriatric population, rising personal healthcare expenditures, increasing chronic diseases incidence, accelerating personal disposable income and improving consumer confidence index are expected to drive the market. However, growth of the industry would be challenged by intellectual property issues, stringent regulatory framework and manufacturing and technology considerations. Few notable trends include progressing product pipeline, increasing product licensing contracts and inclining microbiome research and development activities. In 2020, the outbreak of COVID-19 pandemic has created a favorable impact on the market as the microbiomes-based products sales increased.

The global microbiomes market can be split on the basis of applications into drugs and diagnostics. Currently, drugs occupies the higher share owing to growth in acceptance of probiotics among population and rising prevalence of autoimmune diseases, cancer and gastrointestinal diseases.

The fastest growing regional market is North America owing to rising incidence of lifestyle diseases, increasing focus on human microbiome therapies and growing technological advancements in human microbiome along with next-generation sequencing.

Scope of the report:

  • The report provides a comprehensive analysis of the global microbiomes market, segmented into drugs and diagnostics.
  • The major regional markets (North America, Europe and Asia-Pacific) have been analysed.
  • The market dynamics such as growth drivers, market trends and challenges are analysed in-depth.
  • The competitive landscape of the market, along with the company profiles of leading players (Seres Therapeutics, Inc., Synthetic Biologics, Inc., Evelo Biosciences, Inc., 4D Pharma Plc, Infant Bacterial Therapeutics AB and Takeda Pharmaceutical Company Limited) are also presented in detail.
Key Target Audience:
  • Microbiome-based Manufacturers
  • End Users
  • Consulting Firms
  • Investment Banks
  • Government Bodies & Regulating Authorities


1. Market Overview
1.1 Introduction
1.2 Associated Microbiomes Disorders
Table 1: Association of the Gut Microbiome with Therapeutic Effects of Drugs
1.3 Upcoming Microbiomes-based Products
2. Impact of COVID-19
2.1 Introduction
2.2 Decline in Global GDP Growth
Table 2: Global GDP Growth Rate (2005-2020)
2.3 Change in Organic Traffic
Table 3: Organic Traffic Growth or Decline due to COVID-19 (2020)
2.4 Growth in Spending on Healthcare
Table 4: The U.S. Government Share of Healthcare Spending (2020-2027)
3. Global Microbiomes Market Analysis
3.1 Global Microbiomes Market Value
Table 5: Global Microbiomes Market Value (2018-2024)
3.2 Global Microbiomes Market Value by Applications
Table 6: Global Microbiomes Market Value by Applications (2019)
3.2.1 Global Microbiomes Drugs Market Value
Table 7: Global Microbiomes Drugs Market Value (2018-2024)
3.2.2 Global Microbiomes Drugs Market Value by Therapeutic Area
Table 8: Global Microbiomes Drugs Market Value by Therapeutic Area (2019)
3.2.3 Global Gastroenterology Microbiomes Drugs Market Value
Table 9: Global Gastroenterology Microbiomes Drugs Market Value (2018-2024)
3.2.4 Global Infectious Disease Microbiomes Drugs Market Value
Table 10: Global Infectious Disease Microbiomes Drugs Market Value (2018-2024)
3.2.5 Global Metabolic Disease Microbiomes Drugs Market Value
Table 11: Global Metabolic Disease Microbiomes Drugs Market Value (2018-2024)
3.2.6 Global Oncology Microbiomes Drugs Market Value
Table 12: Global Oncology Microbiomes Drugs Market Value (2018-2024)
3.2.7 Global Immunology Microbiomes Drugs Market Value
Table 13: Global Immunology Microbiomes Drugs Market Value (2018-2024)
3.2.8 Global Microbiomes Drugs Market Value by Technology
Table 14: Global Microbiomes Drugs Market Value by Technology (2019)
3.2.9 Global Microbiomes Diagnostics Market Value
Table 15: Global Microbiomes Diagnostics Market Value (2018-2024)
3.3 Global Microbiomes Market Value by Products
Table 16: Global Microbiomes Market Value by Products (2019)
3.3.1 Global Probiotics Microbiomes Market Value
Table 17: Global Probiotics Microbiomes Market Value (2018-2024)
3.3.2 Global Prebiotics Microbiomes Market Value
Table 18: Global Prebiotics Microbiomes Market Value (2018-2024)
3.4 Global Microbiomes Market Value by Region
Table 19: Global Microbiomes Market Value by Region (2019)
4. Regional Microbiomes Market Analysis
4.1 North America Microbiomes Market Value
Table 20: North America Microbiomes Market Value (2018-2024)
4.2 Europe Microbiomes Market Value
Table 21: Europe Microbiomes Market Value (2018-2024)
4.3 Asia-Pacific Microbiomes Market Value
Table 22: Asia-Pacific Microbiomes Market Value (2018-2024)
5. Market Dynamics
5.1 Growth Drivers
5.1.1 Growing Geriatric Population
Table 23: Global Geriatric Population (2015-2019)
5.1.2 Rising Personal HealthCare Expenditures
Table 24: Global Healthcare Expenditure per Capita (2015-2019)
5.1.3 Increasing Chronic Diseases Incidence
Table 25: Global Chronic Diseases Growth (2019)
5.1.4 Accelerating Personal Disposable Income
Table 26: Global Gross National Income (GNI) per Capita (2015-2019)
5.1.5 Improving Consumer Confidence Index
Table 27: Consumer Confidence Index in US and Europe (2015-2019)
5.2 Key Trends and Developments
5.2.1 Progressing Product Pipeline
Table 28: Global Microbiome-based Product Pipelines
5.2.2 Increasing Product Licensing Contracts
Table 29: Global Microbiome Licensing Deals (2015-2018)
5.2.3 Inclining Microbiome Research and Development Activities
Table 30: Global Microbiome Research and Development Activities (2015-2019)
5.3 Challenges
5.3.1 Intellectual Property Issues
5.3.2 Stringent Regulatory Framework
5.3.3 Manufacturing and Technology Considerations
6. Competitive Landscape
6.1 Global Microbiomes Market
6.1.1 Key Players – Market Cap Comparison
Table 31: Key Players – Market Cap Comparison (2020)
6.1.2 Key Players – Research and Development Expenditures Comparison
Table 32: Key Players – Research and Development Expenditures Comparison (2018/2019)
6.1.3 Key Players – Product Comparison
Table 33: Key Players – Product Comparison (2020)
7. Company Profiles
7.1 Seres Therapeutics, Inc.
7.1.1 Business Overview
7.1.2 Financial Overview
Table 34: Seres Therapeutics Revenues and Net Loss (2015-2019)
7.1.3 Business Strategies
7.2 Synthetic Biologics, Inc.
7.2.1 Business Overview
7.2.2 Financial Overview
Table 35: Synthetic Biologics Net Loss (2015-2019)
7.2.3 Business Strategies
7.3 Evelo Biosciences, Inc.
7.3.1 Business Overview
Table 36: Evelo Biosciences Product Pipeline
7.3.2 Financial Overview
Table 37: Evelo Biosciences Net Loss (2016-2019)
7.3.3 Business Strategies
7.4 4D Pharma Plc
7.4.1 Business Overview
Table 38: 4D Pharma Product Pipeline
7.4.2 Financial Overview
Table 39: 4D Pharma Revenues and Net Loss (2015-2019)
7.4.3 Business Strategies
7.5 Infant Bacterial Therapeutics AB
7.5.1 Business Overview
7.5.2 Financial Overview
Table 40: IBT Net Loss (2015-2019)
7.5.3 Business Strategies
7.6 Takeda Pharmaceutical Company Limited
7.6.1 Business Overview
7.6.2 Financial Overview
Table 41: Takeda Revenues and Net Profit (2016-2020)
7.6.3 Business Strategies

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook